Gilead CEO Daniel O'Day exercises 10,426 RSUs into stock

Gilead Sciences CEO Daniel P. O'Day reported insider stock activity involving restricted stock units linked to Gilead Sciences, Inc. common stock.

Accepted by SEC EDGAR 12/11/2025 - 08:38 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Gilead Sciences CEO Daniel P. O'Day reported insider stock activity involving restricted stock units linked to Gilead Sciences, Inc. common stock. On 12/10/2025, 10,426 restricted stock units were converted into 10,426 shares of common stock, increasing his directly held shares before a related disposition.

On the same date, 4,931 shares of common stock were disposed of at a price of $ 121.34 per share. After these transactions, O'Day directly owned 576,698 shares of Gilead common stock and 88,070 restricted stock units. Each restricted stock unit represents the right to receive one share, and the units follow a four-year vesting schedule in which 25% vest on the first anniversary of the grant date and the remaining balance vests 6.25% quarterly until fully vested.

Insider Trade Summary

10,426 shares exercised/converted

Exercise 3 txns

Insider O'Day Daniel Patrick

Role Chairman & CEO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	10,426	$0.00	$0.00
Exercise	Common Stock	10,426	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	4,931	$121.34	$598K

Holdings After Transaction: Restricted Stock Unit — 88,070 contracts (Direct); Common Stock — 576,698 shares (Direct)

Holdings Before and After: Restricted Stock Unit, 98,496 to 88,070 contracts (Direct); Common Stock, 571,203 to 576,698 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
2. F2. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		M		10,426	A	(1)	581,629	D
Common Stock	12/10/2025		F		4,931	D	$121.34	576,698	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	12/10/2025		M			10,426	(2)	(2)	Common Stock	10,426	(1)	88,070	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Daniel P. O'Day	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.